3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Unknown
1
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Polycystic Ovary Syndrome
7
Neoplasms
3
Melanoma
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Obesity
2
Infertility
2
Glioblastoma
2
Endometrial Neoplasms
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Uterine Cervical Neoplasms
1
TP53 Y220C Mutation
1
Sarcoma, Ewing
1
Sarcoma
1
Prostate Cancer Recurrent
1
Progression-Free Survival
1
Preleukemia
1
Posterior Fossa Ependymal Tumor
1
Osteosarcoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms by Site
1
Metabolic Diseases
1
Medulloblastoma
1
Leukoplakia, Oral
1
Leukemia, Myeloid, Acute
1
Insulin Resistance
1
Hyperandrogenism
1
Interventions
Oxaliplatin
10
pembrolizumab
8
Fluorouracil
8
Leucovorin
7
Paclitaxel
5
Gemcitabine
5
Docetaxel
5
Capecitabine
5
Cyclophosphamide
4
Blood Specimen Collection
4
zolbetuximab
3
fludarabine
3
darolutamide
3
cemiplimab
3
Trastuzumab
3
Taxes
3
Ramucirumab
3
Radiotherapy
3
Radiosurgery
3
Irinotecan
3
trastuzumab deruxtecan
2
enzalutamide
2
durvalumab
2
Standard of Care
2
Nivolumab
2
Folfox protocol
2
Dexamethasone
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
tucatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Adenocarcinoma
×
Metformin
×
Clear all
NCT06687876
2025-07-10
MEMENTO
Amsterdam UMC, location VUmc
Phase 2
Recruiting
14 enrolled